基于PBPK模型理解他汀-罗沙司他药物-药物-疾病相互作用
本研究建立了一种新型虚拟严重慢性肾脏病(CKD)人群,纳入疾病对肾脏和非肾脏通路的影响,并用PBPK模型经四向验证后预测他汀-罗沙司他在严重CKD患者中的DDI风险。验证模型成功预测了患者中底物与抑制剂的药代动力学变化,并在1.25倍和2倍误差内重现了他汀-利福平及健康志愿者中他汀-罗沙司他的DDI。敏感性分析显示严重CKD对他汀PK的影响主要通过肝脏BCRP(瑞舒伐他汀)和OATP1B1/3(阿托伐他汀)介导,患者中他汀-罗沙司他DDI幅度与健康志愿者相似,并确定了PBPK指导的合适剂量方案。
要点
- 严重CKD对他汀PK的影响主要由肝脏BCRP(瑞舒伐他汀)和OATP1B1/3(阿托伐他汀)介导。
- 严重CKD患者中他汀-罗沙司他DDI幅度预测与健康志愿者相似。
- PBPK模型可指导他汀与罗沙司他联用时的剂量方案以降低副作用或治疗失败风险。
核心结论
- 严重CKD患者中他汀-罗沙司他DDI幅度预测与健康志愿者相似。
- PBPK模型成功预测了他汀-罗沙司他DDI并确定了指导剂量方案。
研究设计与样本
- 研究建立了一种新型虚拟严重CKD人群,纳入疾病对肾脏和非肾脏通路的影响。
- 药物和疾病PBPK模型经过四向验证。
主要发现
- 验证的PBPK模型成功预测了患者中底物和抑制剂的药代动力学变化。
- 模型在1.25倍和2倍误差内重现了患者中他汀-利福平DDI和健康志愿者中他汀-罗沙司他DDI。
- 敏感性分析显示严重CKD对他汀PK的影响主要由肝脏BCRP(瑞舒伐他汀)和OATP1B1/3(阿托伐他汀)介导。
临床怎么用
- PBPK模型可用于预测严重CKD患者中他汀-罗沙司他DDI风险并指导合适剂量方案。
局限性
- PBPK模型在严重CKD人群涉及非肾脏通路时预测置信度仍较低。
- 需要更多机制性虚拟疾病人群和稳健验证案例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A different drug-drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug-drug and disease (drug-drug-disease interaction (DDDI)). Physiologically-based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients. However, the prediction confidence of PBPK modeling in the severe CKD population is still low when nonrenal pathways are involved. More mechanistic virtual disease population and robust validation cases are needed. To this end, we aimed to: (i) understand the implications of severe CKD on statins (atorvastatin, simvastatin, and rosuvastatin) pharmacokinetics (PK) and DDI; and (ii) predict untested clinical scenarios of statin-roxadustat DDI risks in patients to guide suitable dose regimens. A novel virtual severe CKD population was developed incorporating the disease effect on both renal and nonrenal pathways. Drug and disease PBPK models underwent a four-way validation. The verified PBPK models successfully predicted the altered PKs in patients for substrates and inhibitors and recovered the observed statin-rifampicin DDIs in patients and the statin-roxadustat DDIs in HVs within 1.25- and 2-fold error. Further sensitivity analysis revealed that the severe CKD effect on statins PK is mainly mediated by hepatic BCRP for rosuvastatin and OATP1B1/3 for atorvastatin. The magnitude of statin-roxadustat DDI in patients with severe CKD was predicted to be similar to that in HVs. PBPK-guided suitable dose regimens were identified to minimize the risk of side effects or therapeutic failure of statins when co-administered with roxadustat.
引用
- Dong J, Prieto Garcia L, Huang Y, et al. Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling. Clin Pharmacol Ther. 2023. PMID: 37376792. doi:10.1002/cpt.2980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。